Dow Jones

44,860.31

0.28%

Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

Regístrate

Inicio
Invertir
Acciones
Estados Unidos
NASDAQ
Ultragenyx Pharmaceutical Inc (RARE)
Ultragenyx Pharmaceutical Inc (RARE) Noticias

RARE

Ultragenyx Pharmaceutical (RARE)

Ultragenyx Pharmaceutical Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:RARE

1 2 3 4 5 6 7 8 9 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
26/11/2024	15:30	GlobeNewswire Inc.	Ultragenyx to Participate in Investor Conferences in December	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
20/11/2024	15:30	GlobeNewswire Inc.	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
12/11/2024	05:03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
09/11/2024	09:30	GlobeNewswire Inc.	Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
05/11/2024	15:01	GlobeNewswire Inc.	Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
29/10/2024	15:05	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
11/10/2024	15:48	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
07/10/2024	07:00	GlobeNewswire Inc.	Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
03/10/2024	15:30	GlobeNewswire Inc.	Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
26/09/2024	07:00	GlobeNewswire Inc.	Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
29/08/2024	15:30	GlobeNewswire Inc.	Ultragenyx to Participate in Investor Conferences in September	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
23/08/2024	06:00	Business Wire	Tactical Resources, a Growing North American Rare Earth Elements Company, to List on NASDAQ	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
01/08/2024	15:05	GlobeNewswire Inc.	Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
25/07/2024	15:05	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
24/07/2024	07:00	GlobeNewswire Inc.	Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
17/07/2024	15:05	GlobeNewswire Inc.	Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
12/07/2024	15:04	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
14/06/2024	16:11	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
13/06/2024	19:49	GlobeNewswire Inc.	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
12/06/2024	16:10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
12/06/2024	15:05	GlobeNewswire Inc.	Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
12/06/2024	15:00	GlobeNewswire Inc.	Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
11/06/2024	16:47	GlobeNewswire Inc.	Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
04/06/2024	15:05	GlobeNewswire Inc.	Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
30/05/2024	15:00	GlobeNewswire Inc.	Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
07/05/2024	15:30	GlobeNewswire Inc.	Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
02/05/2024	15:00	GlobeNewswire Inc.	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
30/04/2024	15:00	GlobeNewswire Inc.	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
30/04/2024	07:00	GlobeNewswire Inc.	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc
25/04/2024	15:30	GlobeNewswire Inc.	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update	NASDAQ:RARE	Ultragenyx Pharmaceutical Inc